Research News

---

Topic: Diagnosis (view all topics)

Tags for topic Diagnosis:

• 1cm-1.9cm
• Ductal Carcinoma In Situ
• Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ)
• Early-stage: Stage IA
• Early-stage: Stage IB
• Early-stage: Stage IIA
• Early-stage: Stage IIB
• Early-stage: Stage IIIA
• Estrogen Receptor Negative Cancer
• Estrogen Receptor Positive Cancer
• HER2/neu Negative Cancer
• HER2/neu Positive Cancer
• HER2 Overexpressing
• Invasive or Infiltrating Ductal Carcinoma
• Invasive or Infiltrating Lobular Carcinoma
• Less than 1cm
• Locally Advanced-stage: Stage IIIB
• Locally Advanced-stage: Stage IIIC
• Luminal A
• Luminal B
• Metastatic
• Metastatic/Advanced-stage: Stage IV
• Non-Metastatic
• Progesterone Receptor Negative Cancer
• Progesterone Receptor Positive Cancer
• Regional
• Triple Negative

View articles by month and year

• Triple-Negative Breast Cancer Seems to Have Abnormal Genes That May Be Treatment Targets

  Published on December 16, 2012 at 5:31 am

  • Tags: Triple Negative, Estrogen Receptor Negative Cancer, HER2/neu Negative Cancer, and Progesterone Receptor Negative Cancer

  A small study has found that many triple-negative breast cancers have abnormal genes that could be targeted by medicines already on the market or being developed.

• Study Analyzes Breast Cancer Genetics, Finds Four Classes of Disease

  Published on September 25, 2012 at 12:00 am

  • Tags: Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  Researchers have done the most thorough analysis of breast cancer genetics to date and found that there are four genetically distinct classes of the disease.

• Breast Cancer’s Hormone Receptor and HER2 Status Can Change After Diagnosis

  Published on June 20, 2012 at 12:00 am

  • Tags: Locally Advanced-stage: Stage IIIB, Locally Advanced-stage: Stage IIIC, Metastatic/Advanced-stage: Stage IV, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Positive Cancer, Metastatic, Non-Metastatic, Regional, Biopsy, FISH Test, IHC Test, Inform HER2 Dual ISH Test, SPoT-Light HER2 CISH, HER2/neu Negative Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...

• Biopsy of Metastatic Cancer May Change Treatment Plan

  Published on June 7, 2010 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Biopsy, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  Research suggests that a breast cancer's characteristics may change if the cancer metastasizes, so doing a biopsy on metastatic cancer may make sense in some cases.

• Number of Circulating Tumor Cells Affects Prognosis

  Published on May 7, 2010 at 12:00 am

  • Tags: Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, and Blood Marker Tests

  New research suggests that knowing the actual number of circulating tumor cells in the blood may some day offer a better estimate of a cancer's prognosis.

• Women Treated for Hormone-Receptor-Negative Cancers More Likely to be Diagnosed with New Cancer in Other Breast

  Published on July 10, 2009 at 12:00 am

  • Tags: Progesterone Receptor Negative Cancer, Estrogen Receptor Negative Cancer, Non-Metastatic, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, and Early-stage: Stage IIIA

  Research shows that women treated for hormone-receptor-negative breast cancer are more than 3 times more likely to be diagnosed with a new cancer (either hormone-receptor-positive or -negative) in the other breast compared to women treated for hormone-receptor-positive breast cancer.

• New Guidelines for Early-Stage Breast Cancer Recommend Treatment Based on Individual Cancer Characteristics

  Published on June 18, 2009 at 12:00 am

  • Tags: Non-Metastatic, Early-stage: Stage 0 -- DCIS (Ductal Carcinoma in Situ), Early-stage: Stage IA, Early-stage: Stage IB, Early-stage: Stage IIA, Early-stage: Stage IIB, Early-stage: Stage IIIA, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  A large group of cancer experts created new guidelines for treating early-stage breast cancer; the guidelines recommend that chemotherapy, targeted therapies, radiation therapy, and hormonal therapy should be based on the characteristics of each individual cancer being treated.

• African American Women More Likely to be Diagnosed with Triple-Negative Disease

  Published on March 25, 2009 at 12:00 am

  • Tags: Progesterone Receptor Negative Cancer, Estrogen Receptor Negative Cancer, and HER2/neu Negative Cancer

  Research offers more evidence that African American women have a higher risk of triple-negative breast cancer compared to women of other races.

• Biopsy of Metastatic Cancer Can Improve Treatment

  Published on March 18, 2009 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, HER2/neu Negative Cancer, HER2/neu Positive Cancer, Progesterone Receptor Negative Cancer, Progesterone Receptor Positive Cancer, Biopsy, Luminal A, Luminal B, Triple Negative, and HER2 Overexpressing

  In some cases, certain "personality" factors of recurrent metastatic breast cancer -- hormone-receptor status and HER2 status -- can be different from the original breast cancer, which may affect treatment decisions.

• Even with New Treatments, No Improvement in Metastatic Breast Cancer Survival

  Published on September 9, 2008 at 12:00 am

  • Tags: Metastatic, Metastatic/Advanced-stage: Stage IV, Estrogen Receptor Negative Cancer, Estrogen Receptor Positive Cancer, Progesterone Receptor Negative Cancer, and Progesterone Receptor Positive Cancer

  A new study finds the average survival time after a diagnosis of metastatic breast cancer hasn't changed much since 1985.